Comparative Pharmacology
Head-to-head clinical analysis: MARLISSA versus NORINYL 1 50 28 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MARLISSA versus NORINYL 1 50 28 DAY.
MARLISSA vs NORINYL 1+50 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MARLISSA is a combination of ethinyl estradiol, a synthetic estrogen, and drospirenone, a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropins, inhibiting ovulation, and alters cervical mucus and endometrial lining.
Norethindrone and ethinyl estradiol combination works by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby inhibiting ovulation. Norethindrone also alters cervical mucus viscosity and endometrial lining, impeding sperm penetration and implantation.
MARLISSA 20 mg orally once daily with or without food.
One tablet orally once daily for 28 days, with 7 inactive tablets during the last 7 days. Each active tablet contains norethindrone 1 mg and ethinyl estradiol 50 mcg.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours (mean 15 hours) in healthy adults. In moderate-to-severe hepatic impairment, half-life may be prolonged to 30-40 hours; no significant change in renal impairment.
Norethindrone: ~8-11 hours; Mestranol: 24 hours (prodrug, ethinyl estradiol half-life ~13-27 hours).
Primarily renal (75-80% as unchanged drug) via glomerular filtration and tubular secretion; 10-15% fecal via biliary excretion; 5-10% metabolized with metabolites also renally eliminated.
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive